BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barrios V, Escobar C. De los ensayos clínicos a la práctica clínica. Evidencias con rivaroxaban en el tratamiento anticoagulante del paciente con fibrilación auricular no valvular. SEMERGEN - Medicina de Familia 2017;43:222-9. [DOI: 10.1016/j.semerg.2016.01.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Pérez Cabeza AI, González Correa JA, Chinchurreta Capote PA, Marqués RB, Mateas FR, Cervantes GR, Prado FM, Tejero SL, Alberca AV. Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice. Future Cardiology 2018;14:9-16. [DOI: 10.2217/fca-2018-0021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Escobar C, Barrios V, Lobos JM, Prieto L. Puntuación SAMe-TT2R2: ¿es útil en todos los pacientes con fibrilación auricular no valvular? Revista Española de Cardiología 2016;69:798. [DOI: 10.1016/j.recesp.2016.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Cerezo-manchado JJ, Navarro-almenzar B, Elvira-ruiz G, García-candel F, Flores-blanco PJ, Caro-martínez C, Manzano-fernández S, García-iniesta N, Sánchez-garcía J, Cabañas-perianes V, Moraleda-jiménez J. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke. Future Cardiology 2018;14:31-7. [DOI: 10.2217/fca-2018-0024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Atienza-martín F, Barrios V, Egocheaga M, Hidalgo R, Marín-montañés N, Ramis C. El método AMFE (Análisis Modal de Fallos y Efectos) aplicado a la anticoagulación de pacientes con fibrilación auricular no valvular. Medicina de Familia SEMERGEN 2019;45:169-79. [DOI: 10.1016/j.semerg.2018.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Pimentel Quezada Y, Bonilla Palomas JL, Gámez López AL, Moreno Conde M, López Ibáñez MC, Gallego de la Sacristana López-Serrano Á. Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use? Future Cardiol 2018;14:47-53. [PMID: 29848089 DOI: 10.2217/fca-2018-0026] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Escobar Cervantes C. Rivaroxaban: from ROCKET-AF trial to routine practice in Spain. Future Cardiol 2018;14:1-2. [PMID: 29848088 DOI: 10.2217/fca-2018-0019] [Reference Citation Analysis]
7 Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, Sánchez MA; the EMIR Study Investigators:. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res 2021;10:583-93. [PMID: 33787316 DOI: 10.2217/cer-2020-0286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Martí E, Segado A, Pastor-galán I, Amat P, Remigia MJ, Solano C, Navarro B. Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Future Cardiology 2018;14:3-8. [DOI: 10.2217/fca-2018-0020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Marín F, Anguita-Sánchez M, Sanmartín M. Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation. Expert Opin Pharmacother 2017;18:67-77. [PMID: 27924633 DOI: 10.1080/14656566.2016.1267140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]